1. Home
  2. ELTX vs CHEC Comparison

ELTX vs CHEC Comparison

Compare ELTX & CHEC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ELTX
  • CHEC
  • Stock Information
  • Founded
  • ELTX 2011
  • CHEC 2024
  • Country
  • ELTX United States
  • CHEC Singapore
  • Employees
  • ELTX N/A
  • CHEC N/A
  • Industry
  • ELTX Biotechnology: Pharmaceutical Preparations
  • CHEC
  • Sector
  • ELTX Health Care
  • CHEC
  • Exchange
  • ELTX Nasdaq
  • CHEC Nasdaq
  • Market Cap
  • ELTX 158.5M
  • CHEC 172.1M
  • IPO Year
  • ELTX N/A
  • CHEC 2025
  • Fundamental
  • Price
  • ELTX $9.15
  • CHEC $9.96
  • Analyst Decision
  • ELTX Strong Buy
  • CHEC
  • Analyst Count
  • ELTX 1
  • CHEC 0
  • Target Price
  • ELTX $13.00
  • CHEC N/A
  • AVG Volume (30 Days)
  • ELTX 110.4K
  • CHEC 51.9K
  • Earning Date
  • ELTX 11-13-2025
  • CHEC 01-01-0001
  • Dividend Yield
  • ELTX N/A
  • CHEC N/A
  • EPS Growth
  • ELTX N/A
  • CHEC N/A
  • EPS
  • ELTX N/A
  • CHEC N/A
  • Revenue
  • ELTX N/A
  • CHEC N/A
  • Revenue This Year
  • ELTX N/A
  • CHEC N/A
  • Revenue Next Year
  • ELTX N/A
  • CHEC N/A
  • P/E Ratio
  • ELTX N/A
  • CHEC N/A
  • Revenue Growth
  • ELTX N/A
  • CHEC N/A
  • 52 Week Low
  • ELTX $4.60
  • CHEC $9.95
  • 52 Week High
  • ELTX $12.62
  • CHEC $10.33
  • Technical
  • Relative Strength Index (RSI)
  • ELTX 51.67
  • CHEC N/A
  • Support Level
  • ELTX $7.87
  • CHEC N/A
  • Resistance Level
  • ELTX $8.99
  • CHEC N/A
  • Average True Range (ATR)
  • ELTX 0.53
  • CHEC 0.00
  • MACD
  • ELTX 0.08
  • CHEC 0.00
  • Stochastic Oscillator
  • ELTX 82.72
  • CHEC 0.00

About ELTX Elicio Therapeutics Inc.

Elicio Therapeutics Inc is a clinical-stage biotechnology company pioneering the development of cancer immunotherapies for patients with limited treatment options and poor outcomes. Its proprietary Amphiphile, or AMP, platform delivers investigational immunotherapeutics directly to the brain center of the immune system the lymph nodes. Its focus is the development of cancer immunotherapies against biologically validated but hard-to-drug targets that can be activated through lymph node trafficking.

About CHEC Chenghe Acquisition III Co. Class A Ordinary Share

Chenghe Acquisition III Co is blank check company.

Share on Social Networks: